DIRECT HEALTHCARE COSTS FOR INDIVIDUALS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: RESULTS FROM A JAPANESE ELECTRONIC HEALTH RECORD DATABASE
Author(s)
Silvia Capucci, MSc1, René Lindholm Cordtz, PhD, MD1, Masaya Otsu, PhD2, Alistair Marsland, MPhys3, Steven Bright, MSc3, Andrew Thompson, PhD3, Hideo Yasunaga4.
1Novo Nordisk A/S, Søborg, Denmark, 2Novo Nordisk Pharma Ltd, Tokyo, Japan, 3LCP Health, Lane, Clark and Peacock LLP, London, United Kingdom, 4University of Tokyo, Tokyo, Japan.
1Novo Nordisk A/S, Søborg, Denmark, 2Novo Nordisk Pharma Ltd, Tokyo, Japan, 3LCP Health, Lane, Clark and Peacock LLP, London, United Kingdom, 4University of Tokyo, Tokyo, Japan.
OBJECTIVES: Transthyretin amyloid cardiomyopathy (ATTR‑CM) is an under-recognised condition with high morbidity and mortality. Its burden is substantial, with prevalence estimates of up to 20% in patients with heart failure and increased myocardial wall thickness. This study aimed to characterise healthcare cost profiles before and after diagnosis for individuals living with ATTR‑CM in Japan.
METHODS: This retrospective open‑cohort study used the Medical Data Vision database, a Japanese claims and electronic health‑record dataset. The study period spanned 1 January 2008 to 30 June 2024. ATTR‑CM was identified using predefined amyloidosis diagnosis codes or tafamidis prescriptions plus a confirmed diagnosis of heart failure, cardiomyopathy or cardiac arrhythmia. Individuals with <6 months of pre‑index data or diagnoses of light‑chain amyloidosis or multiple myeloma were excluded. The index date was the first encounter when all inclusion criteria were met. Serial cross‑sections were constructed to estimate costs, which were inflation‑adjusted to 2024 Japanese yen, converted to USD, and reported as mean per‑person‑per-year (PPPY) values.
RESULTS: The analysis included 17,595 individuals; 39.5% were female and mean age was 71 years (SD 15). Total costs increased from USD 2,235 PPPY at 2-3 years pre‑index to USD 7,146 PPPY in the 6 months pre‑index, before reaching USD 16,109 PPPY 0-6 months post‑index. Inpatient care consistently accounted for the largest share of expenditure. For example, during the first six months after index, inpatient costs peaked at USD 7,885 PPPY, with prescriptions (USD 4,769 PPPY) and laboratory testing (USD 2,571 PPPY) being the next largest contributors, while outpatient care, home care, and emergency visits, represented comparatively small proportions.
CONCLUSIONS: In this Japanese cohort with ATTR-CM, healthcare costs rose steadily before diagnosis and peaked 0-6 months post‑index, likely reflecting intensified diagnostic and acute care needs around the time of ATTR‑CM diagnosis. These findings highlight the substantial healthcare resource and economic burden associated with ATTR-CM.
METHODS: This retrospective open‑cohort study used the Medical Data Vision database, a Japanese claims and electronic health‑record dataset. The study period spanned 1 January 2008 to 30 June 2024. ATTR‑CM was identified using predefined amyloidosis diagnosis codes or tafamidis prescriptions plus a confirmed diagnosis of heart failure, cardiomyopathy or cardiac arrhythmia. Individuals with <6 months of pre‑index data or diagnoses of light‑chain amyloidosis or multiple myeloma were excluded. The index date was the first encounter when all inclusion criteria were met. Serial cross‑sections were constructed to estimate costs, which were inflation‑adjusted to 2024 Japanese yen, converted to USD, and reported as mean per‑person‑per-year (PPPY) values.
RESULTS: The analysis included 17,595 individuals; 39.5% were female and mean age was 71 years (SD 15). Total costs increased from USD 2,235 PPPY at 2-3 years pre‑index to USD 7,146 PPPY in the 6 months pre‑index, before reaching USD 16,109 PPPY 0-6 months post‑index. Inpatient care consistently accounted for the largest share of expenditure. For example, during the first six months after index, inpatient costs peaked at USD 7,885 PPPY, with prescriptions (USD 4,769 PPPY) and laboratory testing (USD 2,571 PPPY) being the next largest contributors, while outpatient care, home care, and emergency visits, represented comparatively small proportions.
CONCLUSIONS: In this Japanese cohort with ATTR-CM, healthcare costs rose steadily before diagnosis and peaked 0-6 months post‑index, likely reflecting intensified diagnostic and acute care needs around the time of ATTR‑CM diagnosis. These findings highlight the substantial healthcare resource and economic burden associated with ATTR-CM.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE320
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Rare & Orphan Diseases